Company to highlight preclinical study of ARV-393, an investigational PROTAC BCL6 degrader, in combination with standard of ...

Arvinas to present preclinical data for PROTAC BCL6 degrader & ARV-393 at 2025 AACR annual meeting in Chicago: New Haven, Connecticut Wednesday, April 23, 2025, 18:00 Hrs [IST] Ar ...

Targeted protein degradation (TPD) is transforming drug discovery by leveraging the cell’s natural protein disposal systems ...

Preferred stocks dropped recently due to inflation fears & panic selling. Learn how rate cuts & inflation fears create discounted buys with strong future returns.

A company in the Netherlands says it has perfected a way to create "graft chimeras" with the skin of one plant and the innards of another ...

A clinical-stage biotech company developing bifunctional small-molecule therapeutics designed to eliminate disease-driving ...

PlayStation is home to some of the most recognizable and popular franchises in gaming, but how do they stack up against one ...

Arvinas, Inc. (NASDAQ:ARVN) unveiled first-in-human data on Friday for its experimental Parkinson’s disease treatment, ARV-102. Results from the randomized, double-blind, placebo-controlled single ...

The new study, published in Nature's journal Cell Death and Disease ... ALK inhibitors specifically bind to the active site of the chimera protein and prevent its kinase activity.

In the trial ARV-102, the company’s investigational PROteolysis TArgeting Chimera (PROTAC ... 90% reduction in peripheral blood mononuclear cells. While LRRK2 is primarily known for its role ...